Dr. Nadler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Nadler Pharma Associates, LLC
7 Waterview Lane
Randolph, NJ 07869Phone+1 973-989-5010Fax+1 973-989-6960
Education & Training
Washington University in St. Louis School of MedicineClass of 1975
Clinical Trials
- A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies Start of enrollment: 2019 Jan 07
Publications & Presentations
PubMed
- 24 citationsErlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case reportLisa Rogers, Patricia LoRusso, Paul I. Nadler, Ghaus M. Malik, Anthony F. Shields
Journal of Neuro-Oncology. 2011-01-01 - 40 citationsErlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trialTomislav Dragovich, Mark S. Huberman, Daniel D. Von Hoff, Eric K. Rowinsky, Paul I. Nadler
Cancer Chemotherapy and Pharmacology. 2007-07-01 - 22 citationsPhase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid TumorsAmita Patnaik, Debra L. Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg
Clinical Cancer Research. 2006-12-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
